Heidi A. Erlacher

Cooley advised Blue Owl Capital (NYSE: OWL), a top asset manager that is redefining alternatives, and HealthCare Royalty (HCRx), a top royalty acquisition company focused on commercial or near-commercial biopharmaceutical products, on a $250 million term loan facility with TG Therapeutics (NASDAQ: TGTX), a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.

Cooley advised the underwriters in the upsized initial public offering of Sagimet Biosciences, a clinical-stage biotechnology company, at $85 million.

Cooley advised VectivBio, a clinical-stage biotech company focused on the discovery and development of treatments for severe, rare gastrointestinal (GI) conditions, on its acquisition by Ironwood, with an estimated aggregate consideration of approximately $1 billion.

Cooley advised CinCor Pharma, a clinical-stage biopharmaceutical company, on its definitive agreement to be acquired by AstraZeneca. M&A partners Rama Padmanabhan and Rowook Park and corporate partners Div Gupta and Sarah Sellers led the Cooley team.

Cooley advised Ovid on its $75 million initial public offering of 5,000,000 shares of common stock. Ovid, which now trades on The NASDAQ Global Select Market as “OVID,” is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders.